Momentum At Indian Innovation Start-Ups: Will Pharma Take Notice?
Executive Summary
Several Indian startups - many with overseas links - appear to be taking a shot at developing, among others, novel treatments targeting multi-drug resistant infections, biobetters and personalized cell based therapy. Funding, though, hasn’t been easy, according to one biopharma advisory firm.
You may also be interested in...
Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows
The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.
Sanofi’s Keeney On Early-Stage Assets, 'Open Dialogue' With Asian Start-Ups
Dr. Adam Keeney, Global Head, External Innovation and R&D Strategy at Sanofi, outlines in an interview with Scrip the company’s interest in early-stage assets and intent to tap into opportunities in Asia-Pacific. He also discusses the region’s role as a digital hub.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.